Site search
2831 results for '' found
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participa
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participa
/
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squa
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squa
/
A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma
A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma
/
A Randomised Double-blind Placebo-controlled Pilot Study of Intravenous Immunoglobulin Replacement Therapy in Lung Transplantation (ACTRN12618001394235)
A Randomised Double-blind Placebo-controlled Pilot Study of Intravenous Immunoglobulin Replacement Therapy in Lung Transplantation (ACTRN12618001394235)
/
IV iron for Treatment of Anaemia before Cardiac Surgery (NCT02632760)
IV iron for Treatment of Anaemia before Cardiac Surgery (NCT02632760)
/
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma(ACTRN12622000856718)
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma(ACTRN12622000856718)
/
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics
/
An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia (ACTRN12619001655134)
An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia (ACTRN12619001655134)
/
A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer’s disease (NCT04592874)
A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer’s disease (NCT04592874)
/
A multicentre, multinational, cohort long-term post-market Clinical [PMCF] follow-up of the safety and efficacy of the Osseo anchored Prostheses for the Rehabilitation of Amputees [OPRA] implant
A multicentre, multinational, cohort long-term post-market Clinical [PMCF] follow-up of the safety and efficacy of the Osseo anchored Prostheses for the Rehabilitation of Amputees [OPRA] implant
/